Results 181 to 190 of about 50,769 (302)

Redox‐Active Guanidines

open access: yesChemElectroChem, Volume 13, Issue 12, 17 June 2026.
Redox‐active guanidines, comprising guanidino‐functionalized aromatics (GFAs) and redox‐active urea azines (RAAs), are electron donors and strong Lewis and Brønsted bases that are used in several applications. They act as redox‐active ligands in bistable coordination compounds and as reagents in dehydrogenative coupling reactions and proton‐coupled ...
Hans‐Jörg Himmel
wiley   +1 more source

Catalytic Conversion of 5‐(Chloromethyl)furfural in Water to 1‐Hydroxyhexane‐2,5‐Dione, α‐Angelica Lactone, and γ‐Valerolactone

open access: yesChemSusChem, Volume 19, Issue 11, 15 June 2026.
Renewable 5‐chloromethylfurfural (CMF), a more stable analog of HMF, was converted to 1‐hydroxy‐2,5‐hexanedione (HHD), a versatile intermediate toward cyclopentenones, pyrroles and aromatic compounds, via a cascade hydrolysis/hydrogenation reaction. α‐Angelicalactone was obtained as a side product. It was also possible to convert CMF to γ‐valerolactone,
Shasha Zheng   +5 more
wiley   +1 more source

A Robust Cost‐Effective Spectrophotometric Method for Nb Determination in Refractory Nb‐doped Gadolinium Zirconate: Overcoming Matrix Dissolution Challenges

open access: yesAnalytical Science Advances, Volume 7, Issue 1, June 2026.
ABSTRACT A simple, robust and cost‐effective analytical methodology was developed for the determination of niobium in highly refractory materials: Nb‐doped gadolinium zirconate (Gd2Zr2O7:Nb) and niobium pentoxide (Nb2O5). The challenge of digesting these matrices was successfully accomplished by establishing two independent dissolution procedures: (i ...
Poonam Verma, Annapurna Chandane
wiley   +1 more source

Addressing Small Data Challenges in Biopharmaceutical Development and Manufacturing: A Mini Review of Multi‐Fidelity Techniques

open access: yesBiotechnology and Bioengineering, Volume 123, Issue 6, Page 1465-1480, June 2026.
ABSTRACT The growing demand for biopharmaceutical products reflects their effectiveness in medical treatments. However, developing new biopharmaceuticals remains a major bottleneck, often taking up to a decade before market approval. Machine learning (ML) models have the potential to accelerate this process, but their success depends on access to large
Mohammad Golzarijalal   +2 more
wiley   +1 more source

Identification of Key Microbial Signatures Associated With Breast Cancer: Machine Learning‐Based Approaches Using Gut Microbiome Data

open access: yesCancer Medicine, Volume 15, Issue 6, June 2026.
This study investigates the potential of the gut microbiome as a non‐invasive biomarker for breast cancer (BC) using a machine learning (ML) framework. Utilizing 16S rRNA gene sequencing data from the NCBI database for 962 individuals (520 BC patients and 442 healthy controls), we processed the sequences through a FastQC, QIIME2, and DADA2 pipeline ...
Md. Tanvir Ahmed   +4 more
wiley   +1 more source

Metabolic Fingerprinting of Urine Reveals Metabolite Changes in Women With Breast Cancer

open access: yesCancer Medicine, Volume 15, Issue 6, June 2026.
This study uses metabolomics to compare urine, plasma and serum metabolite profiles across breast cancer, benign breast disease, symptomatic and healthy controls. Significant metabolic differences—especially in amino acids—were found between BC and other groups, with moderate correlations across biofluids, suggesting potential for non‐invasive BC ...
Nur Aimi Aliah Zainurin   +9 more
wiley   +1 more source

Symplastic Hemangioma of the Limbal Conjunctiva in a Pediatric Patient With Xeroderma Pigmentosa: A Case Report and Review of Literature

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Symplastic hemangioma (SH) is a rare benign vascular lesion marked by striking nuclear atypia in non‐endothelial stromal cells, often mimicking malignancy. It is typically seen in older adults, with only four cases reported to date. Pediatric presentations are exceedingly rare.
Mahir Mahmood   +4 more
wiley   +1 more source

CDK7 as a Potential Exploratory Biomarker for Distinguishing Acute Myocardial Infarction Subtypes via DDR Pathways: Evidence From a Bangladeshi Cohort

open access: yesClinical Cardiology, Volume 49, Issue 6, June 2026.
Differential expression of DNA damage response genes was evaluated in Bangladeshi AMI patients. CDK7 showed significantly higher expression in NSTEMI compared to STEMI, while ATM, OGG1, and NBN showed no subtype‐specific differences, highlighting potential transcriptional heterogeneity between AMI subtypes.
Rifat Hossain Ripon   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy